{"id":"NCT00955682","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612","officialTitle":"Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08-25","primaryCompletion":"2009-12-16","completion":"2012-09-10","firstPosted":"2009-08-10","resultsPosted":"2019-08-06","lastUpdate":"2021-02-26"},"enrollment":342,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningitec™","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"ACTIVE_COMPARATOR"}],"summary":"Subjects were previously vaccinated at 12 to 23 months of age. This extension study starts 24 months after vaccination and the subjects who were vaccinated in the primary study will be enrolled in this extension phase. No new subjects will be enrolled.","primaryOutcome":{"measure":"Number of Subjects With Serum Bactericidal Assay /Activity (rSBA) Against Neisseria Meningitidis Serogroup A, C, W-135 and Y (Using Baby Rabbit Complement) Titres ≥ the Cut-off","timeFrame":"At Month 24 post primary vaccination","effectByArm":[{"arm":"Nimenrix Group Y2","deltaMin":177,"sd":null},{"arm":"Meningitec Group Y2","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":14,"countries":["Finland"]},"refs":{"pmids":["26780033"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":245},"commonTop":["Pain","Erythema","Swelling","Irritability","Somnolence"]}}